Hodgkin's lymphoma (HL) is a rare, curable malignancy, and investigators have made remarkable improvements in treatment of the disease over the past 20 years. Still, physicians face dilemmas in therapy for the disease, and many cured patients live with complications of treatment. The type of therapy given to these patients determines long-term survival rates. The young patient with HL treated in the past had a greater chance of dying of some malignancy other than HL, and at an earlier age than someone who has not had the disease. Relapse therapy can cure approximately 50% of patients, depending on patient- and disease-related features, and failure of initial therapy, once considered an ominous sign, may not be such a poor feature any longer.
Newer therapy options are needed for the disease—not only novel initial therapy designed to treat the patient with minimal complications, but also therapy for those in relapse. In this review, we consider the treatment of HL in younger patients, first evaluating recent clinical trials for early-stage disease, with a special focus on which patients may still need radiotherapy (RT). For advanced disease, prognostic factors may provide information for those wishing to use treatment other than the ABVD regimen (Table 1) or other standard chemotherapy regimens. Finally, investigators should develop methods that minimize the complications of therapy.
Treatment of Early-Stage HL
Most US studies of HL in the past were performed in patients treated with radiotherapy followed by laparotomy. Investigators used these results to form the current staging system for HL. However, following the development of MOPP chemotherapy (Table 1), it became possible to cure patients with chemotherapy, and laparotomy became unnecessary. At the same time, chemotherapy and adjuvant RT was the standard of care in Europe. For these reasons, prognostic-factor systems developed by investigators in Europe and the United States have differed, making comparisons between trials difficult (Table 2).
Regardless, MOPP and therapies that have relied on MOPP-based regimens have gradually given way to treatment with ABVD and similar regimens, not only in the United States, but also in Europe (Table 1). Recent trials suggest that ABVD or variants of this combination with or without RT may still be the best therapy for early-stage HL, regardless of the type of disease presentation, and the potential for complications of therapy may ultimately direct choices of treatment. Guidelines for therapy also still include ABVD as a standard (Table 3).
The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Ha C, Kavadi V, Dimopoulos M, et al: Hodgkin's disease with lymphocyte predominance: Long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys 43:329-334, 1999.
2. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2835-2841, 2004.
3. Le Maignan C, Desablens B, Delwail V, et al: Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103:58-66, 2004.
4. Noordijk E, Thomas J, Ferme C, et al: First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) (abstract 6505). J Clin Oncol 23(16S):561s, 2005.
5. Diehl V, Brillant C, Engert A, et al: HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) (abstract 6506). J Clin Oncol 23(16S):561s, 2005.
6. Rueda A, Marquez A, Guma J, et al: Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: Results after 7 years of a prospective study. Ann Oncol 15:1798-1804, 2004.
7. Dominguez R, Marquez A, Guma J, et al: Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: Results after 7 years of a prospective study. Ann Oncol 15:1798-1804, 2004.
8. Straus D, Portlock C, Qin J, et al: Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483-3489, 2004.
9. Meyer R, Gospodarowicz M, Connors J, et al, for the National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. J Clin Oncol 23:4634-4642, 2005.
10. Colonna P, Jais J, Desablens B, et al: Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 14:1928-1935, 1996.
11. Longo D, Glatstein E, Duffey P, et al: Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol 15:3338-3346, 1997.
12. Soriano J, Dawson L, Kaminski M, et al: Low dose versus high dose radiation therapy in patients with bulky mediastinal Hodgkin's disease (abstract 1171). J Clin Oncol 20:293a, 2001.
13. Klimm B, Engert A, Brillant C, et al: Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD 11 trial of GHSG (abstract 6507). J Clin Oncol 23(16S):561s, 2005.
14. Hirsch A, Vander Els N, Straus D, et al: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function in early-stage Hodgkin's disease. J Clin Oncol 14:1297-1305, 1996.
15. Canelllos G, Duggan D Johnson J, Niedzwiecki D: How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 22:1532-1533, 2004.
16. Canellos G, Anderson J, Propert K, et al: Chemotherapy of advanced Hodgkin's disaese with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
17. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.
18. Dimopoulos M, Cabanillas F, Lee J, et al: Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 11:1108-1111, 1993.
19. Visco C, Vassilakopoulos T, Kliche K, et al: Elevated serum levels of IL-10 are associated with inferior progressioin-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 45:2085-2092, 2004.
20. Gobbi P, Bruglia C, Di Giulio G, et al: The directly measurable tumor burden (TB) is the main prognosticator in Hodgkin's disease (abstract 203). Ann Oncol 13(suppl 2):62, 2002.
21. Montalban C, Garcia J, Abraira V, et al: Influence of biologic markers on the outcome of Hodgkin's lymphoma: A study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 22:1664-1673, 2004.
22. Horning S, Hoppe R, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective randomized trial. J Clin Oncol 20:630-637, 2002.
23. Yahalom J, Edwards-Bennett S, Jacobs J, et al: Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): The Memorial-Sloan-Kettering Cancer Center (MSKCC) experience (abstract 1459). Blood 102:402a, 2003.
24. Chisesi T, Federico M, Levis A, et al: ABVD versus Stanford V versus MEC in unfavorable Hodgkin's lymphoma: Results of a randomised trial. Ann Oncol 13(suppl):S102-S106, 2002.
25. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003.
26. Diehl V, Franklin J, Sieber M, et al: Dose-escalated BEACOPP chemotherapy improves failure-free survival in advanced Hodgkin's disease: Updated results of the German Hodgkin's Lymphoma Study Group (abstract 2474). Blood 95(suppl 1):96, 2005.
27. Ballova V, Ruffer J, Haverkamp H, et al: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann Oncol 16:124-131, 2005.
28. Diehl V, Schiller P, Engert A, et al: Results of the third interim analysis of the HD12 trial of the GHSG: 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkins lymphoma (abstract 85). Blood 102:27a, 2003.
29. Salloum E, Doria R, Farber L, et al: Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. Ca J Sci Am 1:267-278, 1995.
30. Aleman B, van den Belt-Dusebout A, Klokman W, et al: Long-term cause-specific survival of patients treated for Hodgkin's disease (abstract 216). Ann Oncol 13(suppl 2):65, 2002.
31. Andrieu J, Desablens B, Delwail V, et al: High rate of second primary neoplasms (SPN) among Hodgkin's disease (HD) patients (Pts) treated with ABVD, a dacarbazine (DTIC)-containing chemotherapy (CT): Eight year results of a randomized trial of the GOELAMS Group (abstract 1128). Proc Am Soc Clin Oncol 20:283a, 2001.
32. Van Leeuwen F, Klokman W, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994.
33. Schoenfeld S, Gilbert E, Dores G, et al: Acute leukemia (AL) following Hodgkin's lymphoma (HL): A population-based study of over 38,000 patients (abstract 6510). J Clin Oncol 23(16S):562s, 2005.
34. Dores G, Schoenfeld S, Chen D, et al: Long-term cause-specific mortality among 41,146 one-year survivors of Hodgkin lymphoma (HL) (abstract 6511). J Clin Oncol 23(16S):562s, 2005.